Alvine Pharmaceuticals, Inc.

Alvine Pharmaceuticals Closes a $21 Million Series A Financing

Alvine Pharmaceuticals Closes a $21 Million Series A Financing

September 12, 2006

PALO ALTO, Calif. — September 12, 2006 — Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on developing pharmaceutical products for the treatment of celiac sprue, today announced the closing of a $21 million Series A financing. Sofinnova Ventures led the investment round with strong support from Prospect Venture Partners and InterWest Partners. Cargill Ventures and Flagship Ventures also participated in the financing.

Carbon Design Systems

Carbon Fuels Growth With Additional $5M Funding

Carbon Fuels Growth With Additional $5M Funding

September 14, 2006

Next Generation Product Development Underway

WALTHAM, MA -- (MARKET WIRE) -- 09/14/2006 -- Carbon Design Systems -- an innovator in ESL tools for software validation prior to silicon -- announced today that it has raised $5M in its series D round of financing. In addition, Carbon mentioned that Edgar Masri will remain on its board of directors, after being recently appointed the new president and chief executive officer of 3Com, a leader in networking products.

e-Dialog, Inc.

e-Dialog Becomes First E-mail Service Provider to Achieve ISO 27001 Certification for Information Security

e-Dialog Becomes First E-mail Service Provider to Achieve ISO 27001 Certification for Information Security

September 20, 2006

Standard Validates Company’s Commitment to Best-in-Class Data Security Processes and Maximizing Relevance in E-mail Marketing

Adnexus Therapeutics

Adnexus Therapeutics Appoints L. Patrick Gage, Ph.D., as Chairman of the Board of Directors

Adnexus Therapeutics Appoints L. Patrick Gage, Ph.D., as Chairman of the Board of Directors

September 25, 2006

Widely recognized industry leader to guide company advancing breakthrough class of protein therapeutics

Pervasis Therapeutics, Inc.

Pervasis Therapeutics' Vascugel(TM) Initiates U.S. Clinical Trials Following Successful FDA IND Review

Pervasis Therapeutics' Vascugel(TM) Initiates U.S. Clinical Trials Following Successful FDA IND Review

September 27, 2006

Pioneer in regenerative cell-based therapies and devices begins Phase I trials of first biologically-active treatment to ameliorate acute vascular injury

CGI Pharmaceuticals, Inc.

Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications

Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications

October 3, 2006

SOUTH SAN FRANCISCO, Calif. and BRANFORD, Conn., Oct. 3 -- Genentech, Inc. (NYSE: DNA - News) and CGI Pharmaceuticals, Inc. announced today that they have entered into an exclusive global collaboration agreement to discover, develop, manufacture and commercialize therapeutics for an undisclosed target for the potential treatment of multiple oncology and autoimmune indications.

TransMedics, Inc.

TransMedics Receives European Union CE Marking Designation for its Organ Care System

TransMedics Receives European Union CE Marking Designation for its Organ Care System

October 3, 2006

ANDOVER, Massachusetts, October 3 -- TransMedics, Inc., announced today that it has received CE Marking approval for its Organ Care System, the first and only system that allows human donor organs to be maintained in their normal functioning state outside the human body. This designation assures physicians and patients that the Organ Care System is compliant with EU health and safety requirements, allowing TransMedics to market and distribute the system within the European Union, as well as many other countries throughout Asia and the Middle East.

Helicos BioSciences Corporation

Helicos BioSciences Awarded ‘Revolutionary Genome Sequencing Technologies – The $1000 Genome’ Grant

Helicos BioSciences Awarded ‘Revolutionary Genome Sequencing Technologies – The $1000 Genome’ Grant

October 4, 2006

Recognition by National Human Genome Institute to Accelerate Research of Helicos Single Molecule Sequencing Technology

Helicos BioSciences Corporation

Helicos BioSciences Names Louise Mawhinney Vice President & Chief Financial Officer

Helicos BioSciences Names Louise Mawhinney Vice President & Chief Financial Officer

October 12, 2006

CAMBRIDGE, Mass.— October 12, 2006 --Helicos BioSciences, a pioneer in high-speed, high-sensitivity sequencing, announced today that it has named longtime financial executive Louise Mawhinney as Vice President and Chief Financial Officer.

Stanley N. Lapidus, President and CEO of Helicos, said, “We are pleased to have Louise join our executive team. Her operational expertise and deep experience with the financial markets is a great addition to my staff and provides a crucial skill set required for our continued evolution as a company.”

Morphotek, Inc.

Morphotek Raises $40 Million to Advance its Antibody Pipeline

Morphotek Raises $40 Million to Advance its Antibody Pipeline

October 12, 2006

Exton, PA, October 12, 2006 -- Morphotek® Inc., a privately held biopharmaceutical company focused on the discovery and development of therapeutic monoclonal antibodies, announced today the closing of a $40 million Series D financing. The financing was led by Investor Growth Capital of New York and included participation of new investors MDS Capital and Hunt BioVentures as well as existing investors Forward Ventures, Morgenthaler Ventures, SR One, Flagship Ventures, Burrill & Co., CB Health Ventures, and Rock Maple Ventures.